secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0000950170-25-054309
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos directors convert $139K deferred fees to equity: shares + options
-------------------------------------------------------------------------

- Total deferred board service fees of $139,000 from Q3 2024 through Q1 2025 converted to equity.
- Issued 38,269 common shares with aggregate fair value of $111,750.
- Granted 10,904 fully vested stock options at $2.92 exercise price, aggregate fair value $27,250.
- Board elected equity over cash under Non-Employee Directors Compensation Policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000095017025054309/0000950170-25-054309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000095017025054309/tcrt-20250415.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-054309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer